XFOR - X4 Pharmaceuticals - Stock Forecast

Coverage Stock analysts Price Targets & Ratings Chart Insider Trading

XFOR is currently covered by 4 analysts with an average price target of $77.47. This is a potential upside of $75.65 (4156.59%) from yesterday's end of day stock price of $1.82.

X4 Pharmaceuticals's activity chart (see below) currently has 9 price targets and 19 ratings on display. The stock rating distribution of XFOR is 77.78% BUY and 22.22% HOLD.

Stock Analyst Price Targets - Review

Analysts average stock forecasts to be materialized ratio is 24.17% with an average time for these price targets to be met of 99.7 days.

Highest price target for XFOR is $15, Lowest price target is $7, average price target is $11.

Most recent stock forecast was given by SWAYAMPAKULA RAMAKANTH from HC WAINWRIGHT on 02-May-2025. First documented stock forecast 11-Dec-2017.

Currently out of the existing stock ratings of XFOR, 7 are a BUY (77.78%), 2 are a HOLD (22.22%).

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Buy

$7

$5.18 (284.62%)

2 months 25 days ago
(02-May-2025)

0/2 (0%)

$3.27 (87.67%)

Buy

$90

4 months 1 days ago
(26-Mar-2025)

0/2 (0%)

$64.35 (250.88%)

Hold

$15

$13.18 (724.18%)

$30

8 months 9 days ago
(18-Nov-2024)

2/2 (100%)

$3.9 (35.14%)

42

Buy

$120

8 months 13 days ago
(14-Nov-2024)

0/2 (0%)

$54 (81.82%)

Buy

$120

$118.18 (6493.41%)

2 years 2 months 10 days ago
(17-May-2023)

0/1 (0%)

$54 (81.82%)

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

What is XFOR (X4 Pharmaceuticals) average time for price targets to be met?

On average it took 99.7 days on average for the stock forecasts to be realized with a an average price target met ratio 24.17

Which analyst has the current highest performing score on XFOR (X4 Pharmaceuticals) with a proven track record?

KALPIT PATEL

Which analyst has the most public recommendations on XFOR (X4 Pharmaceuticals)?

Kalpit Patel works at B. RILEY and has 3 price targets and 2 ratings on XFOR

Which analyst is the currently most bullish on XFOR (X4 Pharmaceuticals)?

Mayank Mamtani with highest potential upside - $118.18

Which analyst is the currently most reserved on XFOR (X4 Pharmaceuticals)?

Edward Tenthoff with lowest potential downside - -$0

X4 Pharmaceuticals in the News

X4 Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Corporate Updates

4WARD Phase 3 chronic neutropenia trial in full swing; full enrollment on track for 3Q or 4Q 2025 and top-line data in 2H 2026 Additional analyses of mavorixafor clinical trial data increase confidence in successful outcome of 4WARD trial XOLREMDI® net U.S. revenues $3.5 million since May 2024 launch Conference call and webcast today at...

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?